Poor Breast Cancer Survival Associated with Weight Change, Comorbidities

Share this content:

(ChemotherapyAdvisor) – Women who experience a significant weight change following a diagnosis with breast cancer, and who also have comorbidities, experience poor survival, according to a team of US-based researchers. This conclusion is based on a study entitled “Weight Change and Survival after Breast Cancer in the After Breast Cancer Pooling Project,” which was published in the August issue of Cancer Epidemiology, Biomarkers & Prevention.

In this study, the investigators aimed to gain a deeper understanding of the relationship between weight change after a breast cancer diagnosis and the length of survival. To meet their aim, they conducted a retrospective analysis of data of 12,915 women diagnosed with stage I-III breast cancer in China and United States between 1990 and 2006.

For the entire patient population in this study, the mean weight change was 1.6 kg, with 14.7% of the population losing, and 34.7% gaining, weight. Women who had stable weight in the early years postdiagnosis had the lowest overall mortality risk, whereas “a weight loss ≥10% was related to a 40% increased risk of death (HR, 1.41; 95% CI, 1.14–1.75) in the United States and over 3 times the risk of death (HR, 3.25; 95% CI: 2.24–4.73) in Shanghai.” The investigators also reported a lower survival was seen for US-based women who lost weight and had comorbid conditions.  

Based on these findings, the investigators concluded that “prevention of excessive weight gain is a valid public health goal for breast cancer survivors, especially for women with comorbid conditions who may be particularly at risk of weight loss and mortality.”

Abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs